Efficacy and safety of tirzepatide, GLP ‐1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta‐analysis
Pooled result · ≥15% weight lossResult — go to the resultRelative risk 10.24 95% CI 6.42–16.34Authors' conclusion
The superiority of tirzepatide and GLP-1 RA in inducing weight loss and their ability to target multiple metabolic parameters render them promising candidates in the treatment of patients with overweight and obesity.
Study context
- Population
- Patients with overweight and obesity in RCTs31 RCTs · >35,000 patients
- Comparison
- Tirzepatide vs GLP-1 RA and other FDA-approved weight loss drugs
- Outcome
- Weight loss ≥5%, ≥10%, ≥15% and absolute weight loss
Methodological detailsdirect and indirect comparisons, SUCRA ranking, MEDLINE, Embase and Cochrane CENTRAL searched
- Direct and indirect comparisons
- SUCRA ranking
- MEDLINE, Embase and Cochrane CENTRAL searched
Pooled result
≥15% weight loss
Relative risk
10.24
95% CI 6.42–16.34
Tirzepatide 15 mgvs Placebo
RR 10.24 (95% CI 6.42–16.34)
As reported in the abstract
Further pooled results
HbA1c, lipids (total cholesterol, HDL-C, LDL-C, TG) and blood pressure
- Tirzepatide 15 mg ranked in the top three for HbA1c, lipid parameters and blood pressure
Safety
Gastrointestinal adverse effects
- Tirzepatide and GLP-1 RA across all doses had significant increases in GI adverse effects vs placebo
Original publication
Efficacy and safety of tirzepatide, GLP ‐1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta‐analysis. Obesity (Silver Spring). Published 27 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →